货号:A138799
同义名:
硫双二氯酚
/ CP 3438; Actamer
Bithionol是一种抗寄生虫药和可溶性腺苷酸环化酶抑制剂,IC50 为 4 μM,可用于抑制实体肿瘤生长以及细菌、真菌和原生动物感染的研究。


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 靶点 |
|
| 描述 | Bithionol is a potent sAC-specific inhibitor with IC50 value of 4μM[3]. Bithionol inhibited ATP production by working as a classical uncoupler in mitochondria isolated from mouse brain[4]. |
| 作用机制 | Bithionol binds to the sAC-specific, allosteric binding site for the physiological activator. It induces rearrangements of substrate binding residues and of Arg176, a trigger between the active site and allosteric site.[3] |
| Concentration | Treated Time | Description | References | |
| Citrullus vulgaris urease (CVU) | 376.50 µM | 1 hour | Inhibition of CVU activity, IC50 value of 376.50 μM | Molecules. 2016 Nov 26;21(12):1628. |
| Rat locus coeruleus neurons | 1-10 µM | 10 minutes | Potentiated glutamate-induced post-activation inhibition (PAI) in a concentration-dependent manner, without altering glutamate-induced activation | Br J Pharmacol. 2009 Feb;156(4):649-61. |
| KG-1a cells | 7, 14, 28 µM | 12, 24, 48, 72 hours | To evaluate bithionol-induced DNA fragmentation and cell cycle arrest, showing an increased proportion of sub-G0/G1 phase cells. | Cell Death Discov. 2024 Aug 29;10(1):390. |
| MRSA MW2 | 8, 16, 32 μg/mL | 2 hours | To evaluate the bactericidal activity of Bithionol against MRSA MW2 persister cells, results showed complete eradication within 2 hours. | Proc Natl Acad Sci U S A. 2019 Aug 13;116(33):16529-16534. |
| Neuro2A cells | 10 µM | 2 hours | Inhibition of NAPE-PLD activity, significantly reducing synaptamide production | Int J Mol Sci. 2020 Nov 20;21(22):8768. |
| MRSA MW2 | 8, 16, 32 μg/mL | 24 hours | To evaluate the bactericidal activity of Bithionol against MRSA MW2 biofilm persister cells, results showed complete eradication within 24 hours. | Proc Natl Acad Sci U S A. 2019 Aug 13;116(33):16529-16534. |
| Primary cortical neurons | 0.5, 5, 10, 20, 50 µM | 24 hours | To evaluate the toxicity of Bithionol on cortical neurons and its protective effect against Aβ42-induced toxicity. Results showed that Bithionol was not toxic to neurons at tested concentrations and significantly reversed Aβ42-induced toxicity at 5 and 10 μM. | Neurobiol Dis. 2015 Feb;74:144-57. |
| Saccharomyces cerevisiae BY4741 | 0.3, 1, 10, 50 µM | 24 hours | To evaluate the fungicidal activity of Bithionol against Saccharomyces cerevisiae, results showed fungicidal effects at low micromolar concentrations. | mBio. 2016 Aug 2;7(4):e01073-16. |
| Cryptococcus neoformans H99 | 0.3, 1, 10, 50 µM | 24 hours | To evaluate the fungicidal activity of Bithionol against Cryptococcus neoformans, results showed significant fungicidal effects at low micromolar concentrations. | mBio. 2016 Aug 2;7(4):e01073-16. |
| MRSA MW2 | 10 μg/mL | 3 hours | To evaluate the bactericidal activity of Bithionol against MRSA MW2, results showed complete eradication within 3 hours. | Proc Natl Acad Sci U S A. 2019 Aug 13;116(33):16529-16534. |
| Mycobacterium abscessus 19977 | 20 µM | 4 days | Screening compounds for antimicrobial activity against M. abscessus, Bithionol showed excellent antibacterial activity | Antibiotics (Basel). 2024 Jun 5;13(6):529. |
| CV1 monkey kidney cells | 30 µM | 48 hours | To evaluate the effect of Bithionol on SV40 replication, results showed that Bithionol inhibited viral replication nearly 100-fold | Antiviral Res. 2012 Oct;96(1):70-81. |
| Mycobacterium abscessus biofilms | 128 µg/mL | 48 hours | Evaluate the antibiofilm effect of Bithionol, 128 µg/mL could completely eradicate biofilms | Antibiotics (Basel). 2024 Jun 5;13(6):529. |
| Vero monkey kidney cells | 30 µM | 5 days | To evaluate the effect of Bithionol on BKV replication, results showed that Bithionol inhibited viral replication by ~70% | Antiviral Res. 2012 Oct;96(1):70-81. |
| KG-1a, KG-1, Kasumi-1, HL-60 cells | 28 µM | 72 hours | To evaluate the synergistic effect of bithionol with venetoclax, showing a significant reduction in cell viability. | Cell Death Discov. 2024 Aug 29;10(1):390. |
| Mycobacterium abscessus clinical isolates | 0.625 µM to 2.5 µM | Evaluate the antibacterial activity of Bithionol against different subtypes of M. abscessus | Antibiotics (Basel). 2024 Jun 5;13(6):529. | |
| VRSA VRS1 | 8, 16, 32 μg/mL | To evaluate the bactericidal activity of Bithionol against VRSA VRS1 persister cells, results showed complete eradication. | Proc Natl Acad Sci U S A. 2019 Aug 13;116(33):16529-16534. | |
| SAC KO mouse embryonic fibroblasts | 100 µM | To test the effect of Bithionol on tmAC-dependent cAMP formation, results showed that Bithionol did not inhibit tmAC-dependent cAMP accumulation at concentrations up to 100 μM. | J Biol Chem. 2016 Apr 29;291(18):9776-84. | |
| 4-4 cells | 50 µM and 100 µM | To test the effect of Bithionol on sAC activity in cellular systems, results showed that Bithionol caused a dose-dependent decrease in cAMP formation with essentially complete inhibition of sAC-dependent cAMP accumulation at 100 μM. | J Biol Chem. 2016 Apr 29;291(18):9776-84. | |
| Administration | Dosage | Frequency | Description | References | ||
| Transgenic mice (mThy1-APPtg) | Alzheimer's disease model | Intraperitoneal injection | 10 mg/kg | Daily for 1 month | To evaluate the effects of Bithionol on Aβ deposition, synapse loss, and neuronal damage in APP transgenic mice. Results showed that Bithionol significantly reduced Aβ42 oligomer levels, stabilized diffuse-like plaques, and ameliorated synapse loss, neuronal damage, and astrogliosis. | Neurobiol Dis. 2015 Feb;74:144-57. |
| Mice | MRSA thigh infection model | Intraperitoneal injection | 30 mg/kg | Every 12 hours for 3 days | To evaluate the bactericidal effect of Bithionol in combination with gentamicin against MRSA persister cells, results showed significant reduction in bacterial burden. | Proc Natl Acad Sci U S A. 2019 Aug 13;116(33):16529-16534. |
| NSG mice | KG-1a cell leukemia xenograft model | Intraperitoneally | 50 mg/kg | Once daily for two weeks | To evaluate the inhibitory effect of bithionol on AML growth, showing a significant reduction in the percentage of hCD45+ cells in the bone marrow and peripheral blood. | Cell Death Discov. 2024 Aug 29;10(1):390. |
| Mice | Intravenous mouse meningoencephalitis model induced by Cryptococcus neoformans H99 | Oral gavage | 50 mg/kg | Single dose | To evaluate the pharmacokinetics and anti-Cryptococcus neoformans efficacy of Bithionol in mice, results showed limited drug concentrations in brain tissue and limited therapeutic efficacy. | mBio. 2016 Aug 2;7(4):e01073-16. |
| Dose | Horse: 5 mg/kg, 10 mg/kgEvaluation of Anthelmintic Efficacy of Bithionol Paste against Tapeworms Naturally Infected in Horses, by Fecal Examination and Necropsy[3] (p.o.) Mice; 30 mg/kg - 240 mg/kg[4] (p.o.) |
| Administration | p.o. |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
2.81mL 0.56mL 0.28mL |
14.04mL 2.81mL 1.40mL |
28.09mL 5.62mL 2.81mL |
|
| CAS号 | 97-18-7 |
| 分子式 | C12H6Cl4O2S |
| 分子量 | 356.05 |
| SMILES Code | OC1=C(Cl)C=C(Cl)C=C1SC2=CC(Cl)=CC(Cl)=C2O |
| MDL No. | MFCD00055727 |
| 别名 | 硫双二氯酚 ;CP 3438; Actamer; Lorothidol; Bitin; NSC 47129; NSC 9872 |
| 运输 | 蓝冰 |
| InChI Key | JFIOVJDNOJYLKP-UHFFFAOYSA-N |
| Pubchem ID | 2406 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Sealed in dry,2-8°C |
| 溶解方案 |
DMSO: 35 mg/mL(98.3 mM),注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1